| Name | Title | Contact Details |
|---|---|---|
Gary Steen |
Group Chief Technology Officer | Profile |
Seattle based Littlebird believes that building better connections and providing greater communication will lead to better results for you, your caregiver, and child. Littlebird`s state-of-the-art wearable device connects parents with their child anywhere, anytime, with on-demand information about who they are with, where they are located, what they are doing, and how they are feeling. Littlebird`s innovative technology and secure digital platform offers parents unique insights into their child`s safety, health and overall well-being. Littlebird`s 24/7 GPS and cellular connectivity enables up-to-date notifications regarding your child`s location, which "approved" caregiver they are with and what they are doing. Littlebird also provides key metrics regarding your child`s heartrate, daily activity, sleep patterns and much more so you can better understand your child`s specific needs. The intuitively designed app also provides a private chat with photo capabilities connecting you and your caregiver(s) so you never miss a moment of your toddler`s day.
Invatec is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kps Health Plans is a Bremerton, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TherOx, Inc. (TherOx) is a private, venture-financed medical device company based in Irvine, California, dedicated to elevating the standard of care for treatment of heart attack patients. A heart attack is caused when an artery in the heart becomes blocked. Current treatment of heart attack is to reestablish blood flow in the blocked artery as quickly as possible. Typically, this is done with a combination of medication and a percutaneous coronary intervention (PCI) which may include the placement of a (intracoronary) stent. PCI successfully restores blood flow, but damage to the patient’s heart remains. Blood flow in the microvasculature downstream from the blockage is compromised, and critical heart muscle tissue is damaged – or infarcted – due to oxygen deprivation brought on by the heart attack. The intent of SuperSaturated Oxygen (SSO2) Therapy from TherOx is to salvage damaged heart tissue by placing a high concentration of oxygen (~760 – 1,000 mmHg, or 5 – 7 times normal levels) into the patient’s blood plasma and delivering it directly to the area impacted by the heart attack. SSO2 Therapy serves as a complement to PCI and stenting. Immediately following the interventional procedure, proprietary technology from TherOx mixes a pre-specified concentration of “SuperOxygenated” saline solution with the patient’s blood to produce SuperOxygenated blood. The SuperOxygenated blood is then delivered through a catheter to the oxygen deficient tissue. Company research has confirmed in clinical studies that SuperSaturated Oxygen Therapy has the potential to reverse ischemia and may resuscitate tissue that may otherwise die. SSO2 Therapy circulates the patient`s own blood via the existing arterial access site used for the stenting procedure. Thus, no new access site is required. The TherOx DownStream System and DownStream Cartridge bear the CE Mark but are not available for commercial distribution in the EU at this time.
Shelby Residental and Vocational Services is a Memphis, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.